Comparative Pharmacology
Head-to-head clinical analysis: DARICON versus PROPANTHELINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARICON versus PROPANTHELINE BROMIDE.
DARICON vs PROPANTHELINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daricon (oxyphencyclimine) is a competitive antagonist of muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses. It reduces gastrointestinal motility, gastric acid secretion, and smooth muscle spasm by blocking cholinergic activity at effector cells.
Antimuscarinic; competitively blocks acetylcholine at postganglionic muscarinic receptors, inhibiting parasympathetic nerve impulses.
5 mg orally three times daily. Maximum dose: 15 mg per day.
15 mg orally 3 times daily before meals and 30 mg at bedtime; initial dose may be 15 mg 3 times daily.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours; clinical context: allows twice-daily dosing
Terminal half-life 2.5-4 hours; clinically, dosing every 6 hours maintains therapeutic levels.
Renal (70% unchanged, 30% as metabolites); biliary/fecal (10%)
Approximately 70% renal (tubular secretion) as metabolites and unchanged drug; 30% biliary/fecal.
Category C
Category A/B
Anticholinergic
Anticholinergic